China's National Medical Products Administration has approved Chia Tai Tianqing's benmelstobart plus anlotinib for patients with advanced or unresectable alveolar soft part sarcoma. The combination had previously been included in both Breakthrough Therapy and Priority Review pathways by the Center for Drug Evaluation. Benmelstobart is a novel humanized PD-L1 monoclonal antibody developed by Chia Tai Tianqing, while anlotinib is the company's oral multi-target tyrosine kinase inhibitor. The regimen had already secured approvals in China for several other tumor types, including small cell lung cancer, endometrial cancer, renal cell carcinoma, and hepatocellular carcinoma.
The new approval is based on the single-arm open-label TQB2450-Ib-02 study, which evaluated the combination in patients with advanced ASPS who had or had not received prior first-line treatment. The study reported a confirmed objective response rate of 72.41%, with 10.34% of patients achieving a confirmed complete response. Prior chemotherapy exposure did not appear to materially affect response. After a median follow-up of 24.9 months, median progression-free survival had not yet been reached. The article also notes that the combination compared favorably with historical data for anlotinib monotherapy and with published results for similar overseas therapies, while maintaining a controllable overall safety profile without new safety signals.
ASPS is a rare soft-tissue malignancy with high metastatic potential, poor prognosis, limited sensitivity to chemotherapy and radiotherapy, and recurrence rates that can reach 70%. In that setting, approval of an immunotherapy-plus-antiangiogenic combination is clinically meaningful. The source article cites Chinese guideline support for anlotinib as a recommended first-line option in advanced ASPS, and the newly approved combination now offers a potentially stronger alternative for a patient population long underserved by conventional treatment.